Therapie · 2018
[Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Favrelière Sylvie, Lafay-Chebassier Claire, Fauconneau Bernard, Quillet Alexandre, Yéléhé-Okouma Mélissa, Montastruc François, Pérault-Pochat Marie-Christine
Аннотация
INTRODUCTION: Nalmefene, an opioid antagonist, causes withdrawal syndromes in patients exposed to an opioid agonist. Despite its contraindication, this illogical drug association persists, especially with opioid substitution drugs (ODS). We measured the benefits of the modification in the summary of product characteristics (SPC) in March 2015 and the package leaflet of Selincro® in September 2016 on this misuse.
MATERIAL AND METHOD: We analyzed the observations regarding a use of nalmefene with an opioid between September 2014 and August 2017 in the French pharmacovigilance database and the laboratory.
RESULTS: The combination nalmefene and methadone was reported in about half of the cases (46/90). Observations were highest between October 2015 and March 2016 (29/90) and then decreased. Those with self-medication have increased. From October 2016, declarations become rarer.
CONCLUSION: The effect of modifications in the SPC and the package leaflet on the use of nalmefene with ODS was real and progressive.
MATERIAL AND METHOD: We analyzed the observations regarding a use of nalmefene with an opioid between September 2014 and August 2017 in the French pharmacovigilance database and the laboratory.
RESULTS: The combination nalmefene and methadone was reported in about half of the cases (46/90). Observations were highest between October 2015 and March 2016 (29/90) and then decreased. Those with self-medication have increased. From October 2016, declarations become rarer.
CONCLUSION: The effect of modifications in the SPC and the package leaflet on the use of nalmefene with ODS was real and progressive.